While in Figure 5H, Lenvatinib failed to inhibit VEGFR/EGFR signalings in Lenvatinib resistant HCC cells, while C504244 suppresses β-catenin signaling, which meanwhile contributes to decreased EGFR activation (36), which might explain the synergistic effects of these drugs in HCC cells. Here, KDR is linked to hepatocellular carcinoma.